Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Regulus Therapeutics Inc (NASDAQ:RGLS)

Delayed Data
As of Feb 12
 -0.01 / -0.17%
Today’s Change
Today|||52-Week Range
Health Technology
Pharmaceuticals: Other

Company Description

Regulus Therapeutics, Inc. discovers and develops pharmaceutical products. It is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a broad range of diseases. The company intends to focus its proprietary efforts on developing microRNA therapeutics for oncology indications and orphan diseases and is currently advancing several programs toward clinical development in oncology, fibrosis and metabolic diseases. It is developing RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy, and RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 for the treatment of chronic hepatitis C virus infection. Regulus Therapeutics was founded in September 2007 and is headquartered in San Diego, CA.

Contact Information

Regulus Therapeutics, Inc.
3545 John Hopkins Court
San Diego California 92121-1121
P:(858) 202-6300
Investor Relations:
(858) 202-6321



Individual stakeholders37.55%
Other institutional32.60%
Mutual fund holders31.69%

Top Executives

Paul C. GrintPresident, Chief Executive Officer & Director
Joseph P. HaganChief Operating, Financial & Accounting Officer
Michael HuangVice President-Clinical Development
Daniel R. ChevallardVice President-Finance & Accounting
Amy ConradDirector-Investor Relations & Communications